Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 13;9(2):529.
doi: 10.37029/jcas.v9i2.519. eCollection 2023.

Standardised Uptake Value in Organ Confined Prostate Cancer in 68-Ga- Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography Scan and its Correlation with Prostate Specific Antigen Level and Gleason Score

Haider Ali  1 , Syed Rashid-Ul-Amin  1 , Abdul Hai  1
Affiliations

Standardised Uptake Value in Organ Confined Prostate Cancer in 68-Ga- Prostate-Specific Membrane Antigen Positron Emission Tomography-Computed Tomography Scan and its Correlation with Prostate Specific Antigen Level and Gleason Score

Haider Ali et al. J Cancer Allied Spec. .

Abstract

Introduction: A positron emission tomography (PET) scan and a computed tomography (CT) scan are an integral part of oncological imaging and other modalities such as magnetic resonance imaging, CT or bone scintigraphy have some limitations in staging the workup of prostate carcinoma. Combined with tissue-specific markers like prostate-specific membrane antigen (PSMA), positron emitter-based functional imaging results have improved. Our study aimed to determine the Standardised Uptake Value (SUVmax) in prostate adenocarcinoma that is confined to the organ in Ga-68-PSMA PET-CT scans and how it correlates with prostate-specific antigen (PSA) levels and Gleason score (GS).

Materials and methods: This cross-sectional study was conducted at Sindh Institute of Urology and Transplantation (SIUT), Karachi, and includes subjects referred for a Ga68-PSMA PET-CT scan from September 2017 to January 2022. Histopathologic-proven adenocarcinoma prostate patients with organ-confined disease and PSA levels obtained within 6 weeks before the PSMA-PET-CT scan were included in the study. PET-CT images were semi-quantitatively analysed by measuring SUVmax and the result was interpreted using statistical software SPSS version 22.0.

Results: A total of 154 patients were analysed. The mean age of patients was 66.57 ± 8.86 years. The GS of all patients ranges from 6 to 10. The mean and median PSA levels were 32.33 ng/mL (range: 0.004-306.00) and 14.20 ng/mL, respectively. The mean SUVmax of all prostatic lesions was 14.67 ± 12.58 and the median value was 10.76. SUVmax was higher in patients with a PSA level of more than ten than those with a <10. The correlation of SUVmax with PSA and GS showed a significant correlation.

Conclusion: The SUVmax of organ-confined prostate cancer correlates well with PSA level and GS Median SUVmax and PSA directly relate to GS.

Keywords: Ga-68 prostate-specific membrane antigen positron emission tomography-computed tomography; Gleason score; Prostate cancer; Prostate specific antigen; SUVmax.

PubMed Disclaimer

Conflict of interest statement

The author(s) declare(s) that there are no conflicts of interest.

Figures

Figure 1
Figure 1
(a-c) 68-Gallium prostate-specific membrane antigen positron emission tomography (PET) scan and a computed tomography (CT) scan of 72-year-old male with Gleason score 6 and PSS level 7.32 ng/mL showing increased uptake in the peripheral zone in the right lobe of the prostate gland with SUVmax of 7.01 (A=Axial section, B=Coronal C=Sagittal PET-CT fused images)
Figure 2
Figure 2
Scatter plot shows a correlation between prostate specific antigen level and Standardised Uptake Value in prostate cancer
Figure 3
Figure 3
Box plot demonstrates that overall median Standardised Uptake Value is significantly higher with Gleason score of more than 6
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bodar YJ, Koene BP, Meijer D, van Leeuwen PJ, Nadorp S, Donswijk ML, et al. Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate-specific antigen levels and negative prostate biopsies. Urol Oncol. 2022;40:58.e1–7. - PubMed
    1. Wong MC, Goggins WB, Wang HH, Fung FD, Leung C, Wong SY, et al. Global incidence and mortality for prostate cancer:Analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70:862–74. - PubMed
    1. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15:e484–92. - PMC - PubMed
    1. Mottet N, van den Bergh RC, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62. - PubMed
    1. Drost FJ, Osses D, Nieboer D, Bangma CH, Steyerberg EW, Roobol MJ, et al. Prostate magnetic resonance imaging, with or without magnetic resonance imaging-targeted biopsy, and systematic biopsy for detecting prostate cancer:A cochrane systematic review and meta-analysis. Eur Urol. 2020;77:78–94. - PubMed

LinkOut - more resources